168 related articles for article (PubMed ID: 29554967)
1. Tiludronate and clodronate do not affect bone structure or remodeling kinetics over a 60 day randomized trial.
Richbourg HA; Mitchell CF; Gillett AN; McNulty MA
BMC Vet Res; 2018 Mar; 14(1):105. PubMed ID: 29554967
[TBL] [Abstract][Full Text] [Related]
2. Quantitative assessment of intravenous regional limb perfusion of tiludronate as an adjunctive treatment for lameness caused by navicular syndrome in horses.
Schoonover MJ; Whitfield CT; Young JM; Sippel KM; Payton ME
Am J Vet Res; 2018 Dec; 79(12):1313-1320. PubMed ID: 30457899
[TBL] [Abstract][Full Text] [Related]
3. Quantitative assessment of two methods of tiludronate administration for the treatment of lameness caused by navicular syndrome in horses.
Whitfield CT; Schoonover MJ; Holbrook TC; Payton ME; Sippel KM
Am J Vet Res; 2016 Feb; 77(2):167-73. PubMed ID: 27027711
[TBL] [Abstract][Full Text] [Related]
4. Clodronate improves lameness in horses without changing bone turnover markers.
Mitchell A; Wright G; Sampson SN; Martin M; Cummings K; Gaddy D; Watts AE
Equine Vet J; 2019 May; 51(3):356-363. PubMed ID: 30153345
[TBL] [Abstract][Full Text] [Related]
5. Tiludronate infusion in the treatment of bone spavin: a double blind placebo-controlled trial.
Gough MR; Thibaud D; Smith RK
Equine Vet J; 2010 Jul; 42(5):381-7. PubMed ID: 20636772
[TBL] [Abstract][Full Text] [Related]
6. Tiludronate as a new therapeutic agent in the treatment of navicular disease: a double-blind placebo-controlled clinical trial.
Denoix JM; Thibaud D; Riccio B
Equine Vet J; 2003 Jun; 35(4):407-13. PubMed ID: 12880010
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological effects of tiludronate in horses after long-term immobilization.
Delguste C; Amory H; Doucet M; Piccot-Crézollet C; Thibaud D; Garnero P; Detilleux J; Lepage OM
Bone; 2007 Sep; 41(3):414-21. PubMed ID: 17604709
[TBL] [Abstract][Full Text] [Related]
8. Clodronate detection and effects on markers of bone resorption are prolonged following a single administration to horses.
Knych HK; Finno CJ; Katzman S; Ryan D; McKemie DS; Kass PH; Arthur RM
Equine Vet J; 2023 Jul; 55(4):696-706. PubMed ID: 35871470
[TBL] [Abstract][Full Text] [Related]
9. [Use of bisphosphonates in horses - a review].
Düsterdieck-Zellmer KF
Tierarztl Prax Ausg G Grosstiere Nutztiere; 2018 Oct; 46(5):323-333. PubMed ID: 30340242
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of tiludronate in the treatment of horses with signs of pain associated with osteoarthritic lesions of the thoracolumbar vertebral column.
Coudry V; Thibaud D; Riccio B; Audigié F; Didierlaurent D; Denoix JM
Am J Vet Res; 2007 Mar; 68(3):329-37. PubMed ID: 17331024
[TBL] [Abstract][Full Text] [Related]
11. Assessment of a bone biopsy technique for measuring tiludronate in horses: a preliminary study.
Delguste C; Doucet M; Gabriel A; Guyonnet J; Lepage OM; Amory H
Can J Vet Res; 2011 Apr; 75(2):128-33. PubMed ID: 21731184
[TBL] [Abstract][Full Text] [Related]
12. Retrospective Analysis of the Use of Tiludronate in Equine Practice: Safety on 1804 Horses, Efficacy on 343 Horses.
Tischmacher A; Wilford S; Allen K; Mitchell RD; Parkin T; Denoix JM
J Equine Vet Sci; 2022 Aug; 115():104007. PubMed ID: 35577109
[TBL] [Abstract][Full Text] [Related]
13. Clinically relevant doses of tiludronate do not affect bone remodelling in pasture-exercised horses.
Tippen SP; Metzger CE; Sacks SA; Allen MR; Mitchell CF; McNulty MA
Equine Vet J; 2024 Jun; ():. PubMed ID: 38924597
[TBL] [Abstract][Full Text] [Related]
14. Science-in-brief: Bisphosphonate use in the racehorse: Safe or unsafe?
McLellan J
Equine Vet J; 2017 Jul; 49(4):404-407. PubMed ID: 28603949
[No Abstract] [Full Text] [Related]
15. Detection and residence time of bisphosphonates in bone of horses.
Knych HK; Janes J; Kennedy L; McKemie DS; Arthur RM; Samol MA; Uzal FA; Scollay M
J Vet Diagn Invest; 2022 Jan; 34(1):23-27. PubMed ID: 34918585
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of clodronic acid in horses diagnosed with navicular syndrome: A field study using objective and subjective lameness evaluation.
Argüelles D; Saitua A; de Medina AS; Muñoz JA; Muñoz A
Res Vet Sci; 2019 Aug; 125():298-304. PubMed ID: 31351199
[TBL] [Abstract][Full Text] [Related]
17. Effect of oral clodronate on structural damage and bone turnover in rheumatoid arthritis.
Valleala H; Laasonen L; Koivula MK; Risteli J; Konttinen YT
Clin Exp Rheumatol; 2012; 30(1):114-7. PubMed ID: 22260818
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of bisphosphonates in rabbits.
Luurila S; Kautiainen S; Ylitalo P; Ylitalo R
Pharmacol Toxicol; 1999 Jan; 84(1):24-8. PubMed ID: 9974186
[TBL] [Abstract][Full Text] [Related]
19. Effect of clodronate on gene expression in the peripheral blood of horses.
Wilcox CV; Knych HK; Katzman SA; Arthur RM; Rodriguez V; Finno CJ
J Vet Pharmacol Ther; 2024 May; 47(3):187-192. PubMed ID: 38197553
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of tiludronate in horses: A field population study.
Popot MA; Jacobs M; Garcia P; Loup B; Guyonnet J; Toutain PL; Bailly-Chouriberry L; Bonnaire Y
Equine Vet J; 2018 Jul; 50(4):488-492. PubMed ID: 29194746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
